nktr-255
nktr-255: sourced relationships with 1 company · 3 clinical trials tracked.
nktr-255 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could nktr-255 → NKTR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NEKTAR THERAPEUTICS (NKTR) | Phase 1 |
Clinical Trial Registry Records (3)
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
Primary endpoint: Overall survival time distribution
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Primary endpoint: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + Sacituzumab Govitecan Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])
A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) of NKTR-255 in Combination With Cetuximab in R/R HNSCC or CRC for Phase 1b Dose Escalation
Frequently asked questions
Which companies have sourced relationships with nktr-255?
nktr-255 has dated SEC/FDA relationship records for NEKTAR THERAPEUTICS.
How many clinical trials involve nktr-255?
BioSniper tracks 3 clinical trials involving nktr-255.